Pre-analytical in-vitro stability of [-2]proPSA in blood and serum.

Objectives: [-2]proPSA may discriminate prostate cancer from benign biopsy results. We characterized the pre-analytical stability of [-2]proPSA.

Design And Methods: 22 volunteers, total PSA of 4.

hK2 and free PSA, a prognostic combination in predicting minimal prostate cancer in screen-detected men within the PSA range 4-10 ng/ml.

Objectives: The purpose of screening for prostate cancer is to decrease the disease-specific mortality. However not every screen-detected prostate cancer is a threat to the patient's life. The risk of overdetection and subsequent overtreatment in prostate cancer has been recognised.

Multicenter evaluation of an automated assay for troponin I.

Background: Cardiac troponin I (cTnI) is a powerful tool to aid in the diagnosis of myocardial infarction and cardiac muscle damage. We describe an assay that overcomes problems of early assays that were often affected by cTnI degradation, assay interference, poor sensitivity, and imprecision.

Methods: The analytical performance of the Access AccuTnI assay (Beckman Coulter) was evaluated at five institutions.

Use of human glandular kallikrein 2 for the detection of prostate cancer: preliminary analysis.

Objectives: Human glandular kallikrein 2 (hK2) and prostate-specific antigen (PSA) are members of a multigene family of serine proteases that share approximately 80% sequence homology. Both are expressed in the prostate epithelium, are under androgen regulation, are present in serum and seminal fluid, and can form complexes with endogenous protease inhibitors (eg, alpha2-macroglobulin and alpha1-antichymotrypsin). Differences in immunohistochemistry and substrate specificity suggest hK2 may provide unique information for early detection and characterization of prostate cancer.